Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
J Acute Med ; 7(1): 40-43, 2017 Mar 01.
Article in English | MEDLINE | ID: mdl-32995169

ABSTRACT

The NBOMe series is an emerging class of synthetic hallucinogens with limited data available on their use and effects. Whilst toxicity to related substances exist in the literature, no such cases exist for 25G-NBOMe. This case describes a 17-year old male who presented to the Emergency Department with seizures having ingested 25G-NBOMe that had been purchased over the Internet. He was tachycardic, hypotensive and hyperthermic on arrival and required admission to the Intensive Care Unit (ICU) due a persistently low Glasgow Coma Scale (GCS) and profound metabolic derangement. His inpatient stay was prolonged by a persistently high creatine kinase with associated transient acute kidney injury. In contrast, an accompanying friend who had ingested the same drug developed no adverse effects. Our patient's clinical presentation was consistent with reports of adverse outcomes associated with other drugs in the series and demonstrates that acute toxicity can also be seen with 25G-NBOMe with potentially life threatening outcomes.

2.
World J Surg ; 34(11): 2611-20, 2010 Nov.
Article in English | MEDLINE | ID: mdl-20640422

ABSTRACT

BACKGROUND: The best surgical approach to parathyroid cancer is disputed. Recommendations vary and are built on incoherent evidence. High rates of recurrence and death require an in-depth review of underlying findings. METHODS: This retrospective study includes 11 patients with parathyroid cancer who underwent surgery with central and/or lateral neck dissection by a single surgeon between 2005 and 2010. The diagnosis was based on histopathological criteria in all patients. Patterns of lymph node and soft tissue involvement of these and formerly reported patients were analysed based on full-text review of all published cases of parathyroid cancer. RESULTS: In this series only 1 of 11 patients (9.1%) manifested lymph node metastasis. In the literature, lymph node metastases have been reported in only 6.5% of 972 published patients, or in 32.1% of the 196 in whom lymph node involvement was assessed by the authors. They were, with few exceptions, localised in the central compartment. Recurrence in soft tissue is more frequent than in locoregional lymph nodes. CONCLUSION: Oncological en bloc clearance of the central compartment with meticulous removal of all possibly involved soft tissues, including a systematic central lymph node resection, may improve outcomes and should be included in the routine approach to the suspicious parathyroid lesion. There is no need for a prophylactic lateral neck dissection.


Subject(s)
Lymph Nodes/pathology , Parathyroid Neoplasms/pathology , Adult , Aged , Female , Humans , Lymph Node Excision , Lymphatic Metastasis , Male , Middle Aged , Neck Dissection , Parathyroid Neoplasms/surgery , Parathyroidectomy , Retrospective Studies
3.
Diabetes ; 56(2): 285-94, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17259371

ABSTRACT

Proliferation of adipocyte precursors and their differentiation into mature adipocytes contributes to the development of obesity in mammals. IGF-I is a potent mitogen and important stimulus for adipocyte differentiation. The biological actions of IGFs are closely regulated by a family of IGF-binding proteins (IGFBPs), which exert predominantly inhibitory effects. IGFBP-2 is the principal binding protein secreted by differentiating white preadipocytes, suggesting a potential role in the development of obesity. We have generated transgenic mice overexpressing human IGFBP-2 under the control of its native promoter, and we show that overexpression of IGFBP-2 is associated with reduced susceptibility to obesity and improved insulin sensitivity. Whereas wild-type littermates developed glucose intolerance and increased blood pressure with aging, mice overexpressing IGFBP-2 were protected. Furthermore, when fed a high-fat/high-energy diet, IGFBP-2-overexpressing mice were resistant to the development of obesity and insulin resistance. This lean phenotype was associated with decreased leptin levels, increased glucose sensitivity, and lower blood pressure compared with wild-type animals consuming similar amounts of high-fat diet. Our in vitro data suggest a direct effect of IGFBP-2 preventing adipogenesis as indicated by the ability of recombinant IGFBP-2 to impair 3T3-L1 differentiation. These findings suggest an important, novel role for IGFBP-2 in obesity prevention.


Subject(s)
3T3-L1 Cells/drug effects , Insulin Resistance/physiology , Insulin-Like Growth Factor Binding Protein 2/metabolism , Obesity/metabolism , Thinness/metabolism , Adipocytes/metabolism , Adiposity/physiology , Aging/metabolism , Animals , Blood Pressure/physiology , Cells, Cultured , Disease Models, Animal , Fatty Liver/metabolism , Insulin-Like Growth Factor Binding Protein 2/pharmacology , Insulin-Like Growth Factor I/metabolism , Leptin/blood , Mice , Mice, Transgenic , Obesity/prevention & control , Phenotype
4.
Diabetes ; 52(8): 2075-82, 2003 Aug.
Article in English | MEDLINE | ID: mdl-12882925

ABSTRACT

IGFs and their binding proteins (IGFBPs) play a significant role in metabolic regulation, and there is growing evidence that they also exert important vascular effects. IGFBP-1 contributes to glucose counterregulation, and observational studies demonstrate an inverse association between circulating IGFBP-1 levels and cardiovascular risk factors. Furthermore, IGFBP-1 levels are lower in subjects with overt macrovascular disease. We therefore hypothesized that IGFBP-1 exerts potentially beneficial effects, either directly or indirectly, on blood pressure regulation and vascular function. We tested this hypothesis using a unique transgenic mouse, which overexpresses human IGFBP-1, and explored the effect of this protein on metabolic, blood pressure, and vascular homeostasis. IGFBP-1-overexpressing mice exhibited postprandial hyperinsulinemia with preservation of glucocompetence and insulin sensitivity. Blood pressure was unchanged in the fasting state but was significantly lower in transgenic mice after a carbohydrate load. Aortic rings from IGFBP-1-overexpressing mice were hypocontractile in response to vasoconstrictors, and relaxation responses were unimpaired. Basal nitric oxide production was increased and endothelial nitric oxide synthase mRNA expression upregulated in aortae of these mice. Our data suggest that IGFBP-1 plays an important and potentially beneficial role in regulating metabolic and vascular homeostasis.


Subject(s)
Aorta/physiology , Blood Pressure/physiology , Endothelium, Vascular/physiology , Insulin-Like Growth Factor Binding Protein 1/genetics , Animals , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/physiopathology , Gene Expression , Homeostasis/physiology , Insulin/metabolism , Insulin-Like Growth Factor Binding Protein 1/blood , Insulin-Like Growth Factor I/metabolism , Lipids/blood , Male , Mice , Mice, Inbred CBA , Mice, Transgenic , Nitric Oxide Synthase/metabolism , Nitric Oxide Synthase Type II , Nitric Oxide Synthase Type III , Risk Factors , Vasoconstriction/physiology
5.
J Clin Endocrinol Metab ; 88(4): 1687-91, 2003 Apr.
Article in English | MEDLINE | ID: mdl-12679458

ABSTRACT

Fetal IGF-I is a determinant of birth weight, but whether maternal IGF-I plays a significant role is controversial. We sought to examine the relationships among maternal IGF-I, IGF-binding protein (IGFBP)-1, and IGFBP-2, with maternal and newborn anthropometry, in a cohort of 325 nondiabetic pregnant women of African origin. Blood was collected for IGF-I, IGFBP-1, and IGFBP-2 at 9, 25, and 35 wk gestation and in cord blood at delivery. In the second and third trimesters, maternal IGF-I was significantly correlated (P < 0.005) with maternal body mass index and triceps skinfold thickness. Maternal IGFBP-1 and -2 had an inverse correlation (P < 0.0001), with maternal anthropometry. Maternal IGF-I at 35 wk, and fetal IGF-I by cord blood were significantly correlated with birth weight (P = 0.001 and 0.048, respectively). IGFBP-1 in the third trimester and cord blood were negatively correlated with birth weight (P = 0.012 and 0.002). In multiple regression analyses, maternal IGF-I at 35 wk, fetal IGF-I, maternal weight at the first antenatal visit, gender, and gestational age were significant independent factors in the determination of birth weight. In conclusion, maternal IGF-I levels, especially during late pregnancy, positively influence birth weight.


Subject(s)
Anthropometry , Insulin-Like Growth Factor Binding Protein 1/blood , Insulin-Like Growth Factor Binding Protein 2/blood , Insulin-Like Growth Factor I/analysis , Adolescent , Adult , Body Mass Index , Cohort Studies , Female , Fetal Blood/chemistry , Gestational Age , Humans , Infant, Newborn , Nutritional Status , Pregnancy , Prospective Studies , Regression Analysis , Skinfold Thickness
6.
J Clin Invest ; 110(3): 411-8, 2002 Aug.
Article in English | MEDLINE | ID: mdl-12163461

ABSTRACT

IGF binding protein-1 (IGFBP-1) is a secretory product of decidualized endometrium and a major constituent of amniotic fluid. It is thought to modulate the actions of the IGFs on trophoblast cells and is therefore potentially important in regulating placental development and fetal growth. To investigate this hypothesis, we have studied the effects of decidual IGFBP-1 excess on fetoplacental growth in transgenic mice overexpressing human IGFBP-1. Endogenous fetal IGFBP-1 overexpression is associated with a transient impairment of fetal growth in midgestation. Maternal decidual IGFBP-1 excess is also associated with impaired fetal growth in midgestation independent of fetal genotype, indicating placental insufficiency. Our data also demonstrate that amniotic fluid IGFBP-1 is derived almost exclusively from maternal sources. Decidual IGFBP-1 overexpression has a marked effect on placental development. Placental morphology is abnormal in transgenic females due to altered trophoblast invasion and differentiation. These changes result in an increase in placental mass throughout pregnancy. This study provides the first compelling in vivo evidence that IGFBP-1 plays a role in placentation and suggests that IGFBP-1 has a pathological role in preeclampsia, a disorder characterized by shallow uterine invasion and altered placental development.


Subject(s)
Fetal Growth Retardation/metabolism , Insulin-Like Growth Factor Binding Protein 1/physiology , Placenta/embryology , Uterus/embryology , Amniotic Fluid , Animals , Blotting, Western/methods , Decidua/metabolism , Female , Fetal Growth Retardation/embryology , Gene Expression , Humans , Insulin-Like Growth Factor Binding Protein 1/genetics , Insulin-Like Growth Factor Binding Protein 1/metabolism , Insulin-Like Growth Factor II/genetics , Ligands , Liver/embryology , Liver/metabolism , Male , Mice , Mice, Inbred CBA , Mice, Transgenic , Phosphorylation , Placenta/pathology , Uterus/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...